NCT05833217NARecruitingAccepts Healthy Volunteers
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Stanford University
Start Date
6/6/2023
Completion Date
12/31/2025
Summary
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.
Eligibility Criteria
Age Range: 18 years to 80 years
Inclusion Criteria:
* Ages 18 to 80
* BMI ≥ 25 kg/m2
* not currently pregnant
Exclusion Criteria:
Arm 2 (Adipose Tissue Biopsy) exclusions include
* pregnancy
* prior liposuction
* recent change in weight (\> 2 kg in one month)
* bleeding disorders
* anticoagulant use
Arm 3 (healthy controls only) exclusions include patients with
* major organ disease
* diabetes
* history of liposuction
* bariatric surgery
* eating disorders
* psychiatric disorders
* pregnancy or lactation
* recent change in weight (over the past 12 weeks),
* use of weight loss medication or oral steroids
* hematocrit \< 33%
* fasting glucose \>= 126 mg/dL
* blood pressure \>160/100 mmHg
Interventions
PROCEDURE
Adipose Tissue Biopsy
DIAGNOSTIC_TEST
Steady State Plasma Glucose (SSPG) Test
Conditions
Long COVIDInsulin ResistanceInsulin Sensitivity
Locations
Clinical and Translational Research Unit
Palo Alto, California 94304
United States
Stanford Health
Palo Alto, California 94305
United States